This inventor holds 3 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignees: Shire Human Genetic Therapies, Inc., Instrumentation Laboratory. Active years: 2000-2016.
Company Filing History:
2 out of 86 
1 out of 70 Years Active: 2000-2016
Title: Juan Ruiz: Innovator in Genetic Therapies
Introduction
Juan Ruiz is a notable inventor based in Acton, MA (US). He has made significant contributions to the field of genetic therapies, particularly in the development of methods and assays for diagnosing and monitoring genetic disorders.
Latest Patents
Juan Ruiz holds 3 patents, with his latest innovations including the "Mannose receptor C type 1 (MRC1) codon optimized cell line and uses thereof." This patent describes isolated nucleic acid molecules that encode the mannose receptor, C type 1 (MRC1), with a codon-optimized 5' region. It also details methods for detecting antibody production in subjects treated for Gaucher disease using these cells. Another significant patent is for "Assays for detection of glycosaminoglycans," which presents novel methods, assays, and kits for diagnosing and monitoring subjects with mucopolysaccharidoses (MPS). These methods are particularly useful for detecting glycosaminoglycans that correlate with MPS and its severity in various biological samples.
Career Highlights
Throughout his career, Juan has worked with prominent companies in the field, including Shire Human Genetic Therapies, Inc. and Instrumentation Laboratory. His work has focused on advancing genetic therapies and improving diagnostic methods for genetic disorders.
Collaborations
Juan has collaborated with esteemed colleagues such as Marcia Sellos-Moura and Demetrio Sanchez-Martinez. Their combined expertise has contributed to the success of various projects in genetic research and therapy.
Conclusion
Juan Ruiz is a distinguished inventor whose work in genetic therapies has led to important advancements in the diagnosis and treatment of genetic disorders. His patents and collaborations reflect his commitment to innovation in the field.